Skip to main content



Clinical courses


Clinical research courses

  • MHRA recall classification

    The table below explains the new Medicines Recall and Notification classifications and the associated defect risk classification.

    Medicines Recall/Notification Classification : Defect risk classification

    National Patient Safety Alert (NatPSA) equivalent to Class 1 Medicines Recall : The defect presents a risk of death or disability. These alerts will be issued via CAS as National Patient Safety Alerts and will be published on the MHRA website.

  • Caprylhydroxamic acid (KOPSYM)- Dual active for Cosmetics
    Caprylhydroxamic acid is a synthetic chelating agent that helps protect cosmetic formulas from destabilizing metal ions. It also works as a preservative, having the ability to prevent mold growth in water-based formulas. This ingredient has great flexibility since it works in all types of cosmetic formulas, including waterless (anhydrous) and its efficacy is not pH-dependent.
  • Preventive angioplasty does not improve prognosis

    For heart attack patients, treating only the coronary artery that caused the infarction works just as well as preventive balloon dilation of the other coronary arteries, according to a new large study by researchers at Karolinska Institutet and others. The results are published in the New England Journal of Medicine.

  • Discovery of how limiting damage from an asthma attack could stop disease

    Scientists at King’s have discovered a new cause for asthma that sparks hope for treatment that could prevent the life-threatening disease.

  • 100 Rs tablet prevents spread of cancer, breakthrough research by Indian Scientists

    The breakthrough research by TATA memorial centre scientists who have developed a tablet which reduces side effects of cancer treatment and prevent resurgence or relapse of cancer said Dr Rajendra Badwe, Director of the Tata Memorial Centre in an interview with NDTV. The said tablet will be available at an affordable price of Rs. 100 a tablet.

  • First Indian discovered antibiotic gets FDA approval, took 16 years to reach market

    Orchid Pharma, based in Chennai, India, has received approval by the United States Food and Drug Administration (USFDA) for its novel invention, ‘Enmetazobactam’. This development comes in close succession to the recent recommendation for approval by the European Medicines Agency (EMA). Enmetazobactam is the first completely invented-in-India Beta Lactamase Inhibitor.

  • Clinical trial shows rheumatoid arthritis drug could prevent disease

    Results from a Phase 2b clinical trial, published today in The Lancet by researchers led by King’s, provides hope for arthritis sufferers after it was shown that the biologic drug abatacept reduces progression to this agonising chronic inflammatory disease.

  • Anti-Stress Skin Care

    Vinay KumarVinay Kumar Singh.  
    Kumar Organic Products Research Centre Pvt. Ltd.,
    Email :

  • Barrier Repair - A trend in Cosmetics Formulation

    Vinay KumarVinay Kumar Singh.  
    Kumar Organic Products Research Centre Pvt. Ltd.,
    Email :

  • Pharmacological Inhibitor Protects Nerve Cells in ALS Disease

    A new pharmacological inhibitor can intervene in a central cell death mechanism that is responsible for the death of motor neurons and hence important for the progression of the motor neuron disease amyotrophic lateral sclerosis (ALS). A research team led by Prof. Dr Hilmar Bading, neurobiologist at Heidelberg University, examined a neuroprotective molecule that belongs to a novel drug class. It is able to inhibit the interactions of certain proteins and has been successfully tested in a mouse model of ALS and in brain organoids of ALS patients.

Subscribe to Pharmapedia